Carregant...
Long-term safety of tiotropium/olodaterol Respimat(®) in patients with moderate-to-very severe COPD and renal impairment in the TONADO(®) studies
INTRODUCTION: The safety, lung function efficacy, and symptomatic benefits of combined tiotropium and olodaterol in patients with COPD were established in the 1-year TONADO(®) studies (NCT01431274; NCT01431287). As tiotropium is predominantly excreted by the kidneys, the long-term safety profile of...
Guardat en:
| Publicat a: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5987861/ https://ncbi.nlm.nih.gov/pubmed/29910611 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S161489 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|